Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                MCM Regulatory Science

MCM Regulatory Science

                        Animal Rule Information
          Extramural Research
          Intramural Research
          MCMi Regulatory Science Presentations
          Regulatory Science Research Tools Home
          Emergency Preparedness and Response
          Counterterrorism and Emerging Threats
          Medical Countermeasures Initiative (MCMi)
          MCM Regulatory Science
          Characterizing immunity to Ebola and Marburg to support medical countermeasure developmentMCM Regulatory Science Characterizing immunity to Ebola and Marburg to support medical countermeasure development
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              Researchers process biological samples collected from Ebola survivors in DRC (left two images), and a lab technician collects a blood sample from an Ebola survivor. (Images: UCLA)


  Caption
        
      Researchers process biological samples collected from Ebola survivors in DRC (left two images), and a lab technician collects a blood sample from an Ebola survivor. (Images: UCLA)*Using vaccinated and survivor populations of filovirus diseases to inform development of next-generation vaccines and medical countermeasures*

Background | Project description | Project outcomes | Additional reading | Related links

**Performer:**University of California, Los Angeles (UCLA) School of Public Health**Principal investigator:**Anne W. Rimoin, PhD, MPH**Initial contract value:**$1,504,919**Contract modification value:** $1,398,997 (September 2021)**Project dates:**September 2019 – September 2023

Background

The breadth and durability of the human immune response to infection with Ebola virus and Marburg virus—as well as the vaccine-induced immune response in individuals vaccinated with investigational vaccines against those viruses—is not well understood. This lack of understanding can create challenges for the development of medical countermeasures (MCMs) to combat these threats.

To help address these challenges, FDA is supporting a study of the immune response in Ebola Virus disease and Marburg Virus disease survivors as well as in individuals vaccinated with investigational Ebola vaccines. This study will help the evaluation of the performance of existing MCMs while also supporting the development of next-generation MCMs.

Project description

UCLA—in collaboration with the Congolese Institut National de la Recherche Biomédicale (National Institute for Biomedical Research) (INRB)—will expand a biobank of plasma and peripheral blood mononuclear cell (PBMC) samples to help support the development of MCMs against Ebola and Marburg viruses.

The Ebola biobank will include plasma and PBMC samples from survivors of Ebola virus disease (EVD), extending back to the first reported outbreak in Yambuku in 1976. In addition, the Ebola biobank will include plasma and PBMC samples from individuals vaccinated with investigational Ebola vaccines and control participants. The Marburg biobank will include plasma and PBMC samples from survivors of Marburg virus disease (MVD) from outbreaks that occurred in 2017 and 1998. The project will also identify and collect samples from additional survivors of MVD for inclusion in the biobank. These samples will be identified through outbreak line listings, key contact interviews, and serology results of high-risk populations such as health care workers.

UCLA will use these biobanks—in collaboration with Stanford University, the National Institutes of Health Integrated Research Facility, and the University of Hawaii—to characterize the natural immunity in EVD and MVD survivors as well as the durability and correlates of vaccine-induced immunity to EVD.

Project outcomes

Comprehensive evaluation of the anti-GP antibody response of the rVSV-ZEBOV vaccine via FANG and FRNA assay of vaccinees and control populations
	Identification of potential correlates of vaccine-induced immunity via characterization of immune profiles of vaccinated populations (using sub-cohorts from Objective 1) via Western blot, GeneXpert, Lehrer multiplex pan-filovirus assay on vaccine sub-cohorts
	Characterization of long-term (life course) natural immunity in EVD survivors via CyTOF, Lehrer multiplex pan-filovirus assay, and Elispot assay of EVD survivors
	Characterization of correlates of natural immunity of MVD survivors via Lehrer multiplex pan-filovirus assay, CyTOF mass cytometry and assessment of neutralizing antibodies via PRNT and FRNA assays
	Characterization of the durability of vaccine-induced humoral immunity to Ebolavirus and Marburgvirus
	Characterization of the correlates of vaccine-induced immunity to Ebolavirus and MarburgvirusThese efforts will contribute to the regulatory science knowledge base critical to developing new medical countermeasures, and ultimately improve prevention, treatment, and care strategies for patients affected by EVD and MVD.

*This project was funded through the MCMi Regulatory Science Extramural Research program and is supported through partnership with the Defense Threat Reduction Agency.*

Additional reading

Health topics: Ebola virus disease (World Health Organization Regional Office for Africa)
	Years of Ebola Virus Disease Outbreaks: 40 Years of Ebola Virus Disease Around the World (CDC)
	Henao-Restrepo, A. M., Camacho, A., Longini, I. M., et al. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). In The Lancet (Vol. 389, Issue 10068, pp. 505–518). Elsevier BV. https://doi.org/10.1016/s0140-6736(16)32621-6Related links

Ebola Preparedness and Response Updates from FDA
	Survivor Studies: Better Understanding Ebola’s After-Effects to Help Find New Treatments
	Regulatory Science Extramural Research

                                                                                  Content current as of:
      02/01/2023
              
              
Topic(s)
			  Research
				    				       				    				       BiologicalHealth Topic(s)
			  EbolaMCM Regulatory Science

          
                        Animal Rule Information
          Extramural Research
          Intramural Research
          MCMi Regulatory Science Presentations
          Regulatory Science Research Tools
 Subscribe
                        Sign up to receive email alerts on emergency preparedness and response topics from FDA, including regulatory science related to medical countermeasures and emerging infectious diseases.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop